ROCKVILLE, Md. and MIAMI, July 12, 2021 /PRNewswire/ — Ceros Financial Services introduced that it has appointed Cosme Ordoñez as Managing Director, Funding Banking Healthcare. Dr. Ordoñez, who has greater than 20 years of expertise in capital markets, fairness analysis and funding banking, will probably be concerned with due diligence of company finance and capital elevating actions for Ceros Capital Markets.
Ceros focuses on funding in rising medical know-how and medical machine firms, with an emphasis on start-ups in South Florida. Dr. Ordoñez will work intently with Ceros’ Miami workplace, stated Mark Goldwasser, CEO of Ceros Monetary Companies.
“Cosme involves us with intensive credentials and deep expertise spanning each finance and medication, in addition to familiarity with early-stage firms. He’s additionally multi-lingual, fluent in Spanish and Portuguese, which is able to facilitate our staff’s analysis and funding recommendation for LatAm traders and firms. His experience will probably be invaluable as we proceed to pursue strategic investments in promising and disruptive medtech start-ups,” Goldwasser stated.
Previous to Ceros, Dr. Ordoñez was Managing Director, Senior Biotechnology Analyst at Nationwide Securities Corp. Beforehand, he served with Noble Capital Markets, the place in his most up-to-date place he led the Life Sciences Fairness Analysis staff. He joined Noble as a Managing Director on the Healthcare Funding Banking staff, aiding rising biotechnology firms to boost capital via non-public and public choices.
Dr. Ordoñez was the co-founder of Ciclofilim Prescription drugs, a startup biotech primarily based in San Diego. Beforehand, he was Director of Healthcare Investments at Distinction Capital, a service provider and enterprise capital funding financial institution.
Dr. Ordoñez has a Physician in Drugs diploma and a Ph.D. in Experimental Drugs from McGill College and accomplished a Put up-Doctoral Fellowship on the Karolinska Institute in Stockholm, Sweden. As an fairness analysis analyst he achieved high rankings kind Brendan Wooden Worldwide and Starmine. Dr. Ordoñez has revealed on quite a few subjects within the areas of oncology, virology and immunology. He holds Sequence 79, 7, 86 and 87 FINRA licenses.
Ceros is concentrating on to boost $100 million over the following twelve months for funding in early-stage medical know-how and medical machine firms, Goldwasser stated. Prior to now 14 months, Ceros has accomplished about $65 million in transactions within the medtech sector.
Earlier this yr, the agency co-led a $96 million financing spherical for Fort Lauderdale-based Memic Revolutionary Surgical procedure to assist commercialization of Memic’s Hominis® robotic-assisted platform, which options miniature humanoid-shaped robotic arms designed to duplicate a surgeon’s motions. Different Ceros investments embrace OrthoSensor, which has developed a sensor-assisted machine used throughout knee surgical procedure that sends real-time knowledge to an working room monitor, aiding surgeons’ decision-making; Dermasensor, which designs non-invasive instruments that use machine studying and spectroscopy to guage pores and skin lesions for most cancers; and Insightec, which makes use of guided centered ultrasound tools for non-invasive mind surgical procedure.
About Ceros Monetary Companies, Inc.
Ceros Monetary Companies, Inc. Member FINRA/SIPC (www.cerosfs.com) affords a complete asset administration and mutual fund suite for monetary advisors. Ceros companies embrace RIA custody, hybrid advisors, company RIA, mutual fund advisory and distribution, and an outsourced commerce desk. As well as, Ceros Capital Markets, a division of Ceros Monetary, is a digital and conventional platform for the distribution of major choices in medical gadgets and secondaries in unicorns by way of Particular Function Automobiles (SPVs).
Investing within the securities markets entails threat, together with lack of principal. Personal Placements usually are not applicable for all traders. Most if not all investments in Personal Placements are illiquid and lots of such investments are speculative in nature. Investing in a Personal Placement can lead to a big threat of lack of principal. Danger components for personal choices are listed within the Personal Placement Memorandum; and must be learn rigorously previous to investing.
SOURCE Ceros Monetary Companies, Inc.